Quan H - Search Results

1

A modular biomimetic strategy for the synthesis of macrolide P-glycoprotein inhibitors via Rh-catalyzed C-H activation.

Chen L, Quan H, Xu Z, Wang H, Xia Y, Lou L, Yang W. Chen L, et al. Among authors: quan h. Nat Commun. 2020 May 1;11(1):2151. doi: 10.1038/s41467-020-16084-0. Nat Commun. 2020. PMID: 32358512 Free PMC article.

2

Pd-Catalyzed Decarboxylative Olefination: Stereoselective Synthesis of Polysubstituted Butadienes and Macrocyclic P-glycoprotein Inhibitors.

Song B, Xie P, Li Y, Hao J, Wang L, Chen X, Xu Z, Quan H, Lou L, Xia Y, Houk KN, Yang W. Song B, et al. Among authors: quan h. J Am Chem Soc. 2020 Jun 3;142(22):9982-9992. doi: 10.1021/jacs.0c00078. Epub 2020 May 20. J Am Chem Soc. 2020. PMID: 32352771

3

YHHU0895, a novel synthetic small-molecule microtubule-destabilizing agent, effectively overcomes P-glycoprotein-mediated tumor multidrug resistance.

Zhao H, Quan H, Xie C, Xu Y, Xie F, Hu Y, Lou L. Zhao H, et al. Among authors: quan h. Cancer Lett. 2012 Jan 1;314(1):54-62. doi: 10.1016/j.canlet.2011.09.013. Epub 2011 Sep 19. Cancer Lett. 2012. PMID: 21982683

4

AKT is critically involved in the antagonism of BRAF inhibitor sorafenib against dabrafenib in colorectal cancer cells harboring both wild-type and mutant (V600E) BRAF genes.

Wang H, Quan H, Lou L. Wang H, et al. Among authors: quan h. Biochem Biophys Res Commun. 2017 Jul 15;489(1):14-20. doi: 10.1016/j.bbrc.2017.05.110. Epub 2017 May 20. Biochem Biophys Res Commun. 2017. PMID: 28536078

5

Synthesis and biological evaluation of 2,4,5-substituted pyrimidines as a new class of tubulin polymerization inhibitors.

Xie F, Zhao H, Li D, Chen H, Quan H, Shi X, Lou L, Hu Y. Xie F, et al. Among authors: quan h. J Med Chem. 2011 May 12;54(9):3200-5. doi: 10.1021/jm101388d. Epub 2011 Apr 11. J Med Chem. 2011. PMID: 21480626

6

p38 MAPK, but not ERK1/2, is critically involved in the cytotoxicity of the novel vascular disrupting agent combretastatin A4.

Quan H, Xu Y, Lou L. Quan H, et al. Int J Cancer. 2008 Apr 15;122(8):1730-7. doi: 10.1002/ijc.23262. Int J Cancer. 2008. PMID: 18074350

7

Aberrant modulation of ribosomal protein S6 phosphorylation confers acquired resistance to MAPK pathway inhibitors in BRAF-mutant melanoma.

Gao MZ, Wang HB, Chen XL, Cao WT, Fu L, Li Y, Quan HT, Xie CY, Lou LG. Gao MZ, et al. Acta Pharmacol Sin. 2019 Feb;40(2):268-278. doi: 10.1038/s41401-018-0020-z. Epub 2018 May 18. Acta Pharmacol Sin. 2019. PMID: 29777202 Free PMC article.

8

RON confers lapatinib resistance in HER2-positive breast cancer cells.

Wang Q, Quan H, Zhao J, Xie C, Wang L, Lou L. Wang Q, et al. Among authors: quan h. Cancer Lett. 2013 Oct 28;340(1):43-50. doi: 10.1016/j.canlet.2013.06.022. Epub 2013 Jun 27. Cancer Lett. 2013. PMID: 23811285

9

NL-103, a novel dual-targeted inhibitor of histone deacetylases and hedgehog pathway, effectively overcomes vismodegib resistance conferred by Smo mutations.

Zhao J, Quan H, Xie C, Lou L. Zhao J, et al. Among authors: quan h. Pharmacol Res Perspect. 2014 Jun;2(3):e00043. doi: 10.1002/prp2.43. Epub 2014 Apr 7. Pharmacol Res Perspect. 2014. PMID: 25505589 Free PMC article.

10

Aberrant intracellular metabolism of T-DM1 confers T-DM1 resistance in human epidermal growth factor receptor 2-positive gastric cancer cells.

Wang H, Wang W, Xu Y, Yang Y, Chen X, Quan H, Lou L. Wang H, et al. Among authors: quan h. Cancer Sci. 2017 Jul;108(7):1458-1468. doi: 10.1111/cas.13253. Epub 2017 May 23. Cancer Sci. 2017. PMID: 28388007 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,286 results

Search Page

Filters